Kevin T McDonagh

Title: Kevin T McDonagh: Innovator in Multidrug Resistance Gene Research

Introduction

Kevin T McDonagh is a notable inventor based in Silver Spring, MD (US). He has made significant contributions to the field of genetic research, particularly in the area of multidrug resistance genes. His work has implications for cancer treatment and gene therapy.

Latest Patents

Kevin T McDonagh holds a patent for the expression of human multidrug resistance genes. His patent, titled "A DNA sequence for a human mdr1 gene, which encodes p-glycoprotein," describes a method that prevents truncation of p-glycoprotein upon expression. This innovation allows for improved selection of cells expressing the human mdr1 gene, facilitating the identification of retroviral producer clones and enabling mdr gene transfer into primary cells. The method involves using a staining material, such as rhodamine 123, to differentiate cells based on color, which has proven effective in identifying genetically engineered hematopoietic stem cells.

Career Highlights

Throughout his career, Kevin has worked with various organizations, including Genetic Therapy, Inc. and the United States of America as represented by the Department of Health. His research has contributed to advancements in gene therapy and the understanding of drug resistance in human cells.

Collaborations

Kevin has collaborated with esteemed colleagues such as Arthur W Nienhuis and Paul Tolstoshev. These partnerships have furthered his research and expanded the impact of his work in the scientific community.

Conclusion

Kevin T McDonagh's innovative research in multidrug resistance genes has paved the way for advancements in gene therapy and cancer treatment. His contributions continue to influence the field and inspire future research endeavors.